Korean device companies keep reaching our market access desk with the same question, usually in the first email: our device is approved by Korea’s Ministry of Food and Drug Safety (MFDS), we do not have FDA clearance or a CE certificate yet, so can we still register in Latin America, and does the Korean approval shorten anything? The follow-up is almost always: we have a new version still under MFDS review, can we file that one?
I’m Julio Martinez-Clark, CEO of bioaccess®. We hold device registrations in Latin America for foreign manufacturers and run first-in-human and early feasibility device studies in the region. Here is the short version, then the detail by country.
The short answer
- Mexico (COFEPRIS): yes, MFDS counts. Since the July 2025 equivalence agreement, COFEPRIS recognizes approvals from the IMDRF Management Committee members and full MDSAP members, and South Korea is on that list. The abbreviated filing (homoclave COFEPRIS-04-050) has a 30-business-day decision target for a complete file.
- Brazil (ANVISA): no shortcut. ANVISA’s optimized review under IN 290/2024 relies only on the FDA, Health Canada, Japan’s MHLW and Australia’s TGA. An MFDS-only device goes through ordinary registration.
- Colombia (INVIMA): no equivalency route for anyone. The Korean approval is supporting evidence, not a pathway.
- Chile (ISP): the question is whether your device is under mandatory control. Decreto Exento N° 25 (March 2026) is pulling 39 device and IVD types into ISP registration, and ISP has not yet published the technical instruction that will say what evidence it accepts.
- The new version: reliance borrows a decision that already exists. A version still under MFDS review has nothing to rely on yet.
Mexico: where an MFDS approval does real work
COFEPRIS used to recognize only FDA, Health Canada and Japanese approvals for devices. On 18 July 2025 it published the agreement that replaced that model with a reference-authority list tied to the IMDRF Management Committee and full MDSAP members: Australia, Brazil, Canada, China, the European Union, Japan, Russia, Singapore, South Korea, Switzerland, the United Kingdom and the United States. For a Korean manufacturer, that makes Mexico the most natural first Latin American market.
The conditions are where teams get caught:
- Identical device. Design, components, intended use, operating principle and manufacturing must match what MFDS approved. A different accessory set, a changed processor or a new indication can push you back to the standard route.
- Ordinary review only. The reference approval must come from a full review, not an emergency or accelerated mechanism.
- Documents still matter. You still file a technical summary (description, conformity assessment presented to the reference authority, clinical evaluation, risk analysis, packaging, finished-product certificate and, for Class II and III, tecnovigilancia), with legal documents legalized or apostilled and translated into Spanish by a certified translator.
- A Mexican registration holder. Reliance shortens COFEPRIS’s review. It does not remove the need for a local holder who answers for the registration and post-market duties.
Thirty business days is the target for a complete file. Plan for longer in practice, and put your effort into making the file complete on the first submission, because that is what you control.
Brazil: ordinary registration, plan for it
IN 290/2024 created ANVISA’s optimized analysis for Class III and IV devices based on prior approval by an equivalent foreign regulatory authority (AREE). The AREE list is short: the US FDA, Health Canada, Japan’s MHLW and Australia’s TGA. MFDS is not on it, and neither is a CE certificate on its own. I cover the full comparison in our regional reliance guide.
So an MFDS-only device follows ordinary registration under RDC 751/2022, with a Brazilian registration holder, Portuguese labeling and instructions for use, ANVISA GMP certification for Class III and IV, and INMETRO certification where it applies to electrical equipment. None of that is a reason to skip Brazil. It is a reason to budget the timeline honestly and to start the GMP certification track early, because that step usually sets the critical path.
Colombia: evidence, not equivalency
Colombia regulates devices under Decreto 4725 de 2005, with its own Class I, IIa, IIb and III scheme. There is no abbreviated equivalency pathway for devices from any country, so MFDS-only is not a disadvantage compared with FDA-only. For imported devices, INVIMA asks for a certificate of free sale, and the higher classes need the clinical and technical evidence behind the approval. For a device made and approved in Korea, build the file around the Korean certificate (apostilled, since both countries are in the Apostille Convention) and confirm early that the document you plan to use matches what INVIMA expects for your class. That one check avoids the most common deficiency letter we see.
Chile: check the decree list before anything else
For years Chile required ISP registration for only a short list of named products, so many devices entered with a strong distributor and an importer of record. That is changing. Decreto Exento N° 25, published on 19 March 2026, brings 39 numbered device and IVD types under mandatory sanitary control in two waves. The first wave, with a deadline of 19 March 2028, includes cardiovascular implants, heart valves, cochlear implants, orthopedic and soft-tissue implants and insulin pumps, among others. The second wave runs to 19 March 2029.
ISP has up to 12 months from publication to issue the technical instruction for conformity verification, and voluntary filing opens only after that. As of this writing it has not been published, so nobody can tell you yet whether ISP will lean on an MFDS approval, or how much. What you can do now:
- Map your product against the decree’s numbered list, not against a distributor’s memory of the old rules.
- If you are on the list, treat any near-term launch as a bridge and prepare a Spanish technical file so you can file as soon as the instruction appears.
- Choose a local party who can carry the registration and tecnovigilancia later, not just import.
Our two Chile briefs go deeper: Chile’s easy market ends in 2028 and what Decreto Exento N° 25 changes.
The new-version trap
This is the part that costs Korean companies the most time. If version 1 is MFDS-approved and version 2 (say, a redesigned external component) is still under MFDS review, the only device you can rely on in Mexico today is version 1, exactly as approved. Filing version 2 before MFDS decides means the standard route at best. My usual advice:
- If version 2 will replace version 1 within a few months, prepare the Mexican file now and submit the day the MFDS approval issues.
- If you need revenue sooner, register version 1 and plan a modification filing for version 2, knowing that changes to a registered device have their own procedure and timeline.
- In Brazil and Colombia the version question still matters for the technical file, but it does not change the pathway, because MFDS is not a reliance basis there anyway.
A decision rule I give Korean founders
- Start with Mexico if the device is identical to what MFDS approved. It is the one large market where your approval shortens review.
- Run Colombia in parallel. Your position there is the same as an FDA-cleared competitor’s.
- Budget Brazil as ordinary registration, unless an FDA, Canadian, Japanese or Australian approval is close enough to wait for.
- For Chile, decide product by product against Decreto Exento N° 25 and the ISP instruction.
FAQ
Does COFEPRIS accept a Korean MFDS approval for abbreviated device registration?
Yes. Since the July 2025 agreement, South Korea is one of the reference authorities COFEPRIS recognizes, as an IMDRF Management Committee member. The device must be identical to the MFDS-approved one, and you file under COFEPRIS-04-050.
Does an MFDS approval qualify for ANVISA’s optimized review under IN 290/2024?
No. ANVISA relies only on the FDA, Health Canada, Japan’s MHLW and Australia’s TGA. An MFDS-only device follows ordinary registration.
Is there a reliance pathway in Colombia for MFDS-approved devices?
No, and there is none for FDA-cleared devices either. INVIMA reviews under Decreto 4725 de 2005 and uses the foreign approval as evidence.
Does Chile require ISP registration for my device?
It depends on whether the device is on the mandatory-control list, which Decreto Exento N° 25 expands to 39 more types with deadlines in 2028 and 2029. Check the numbered list first.
Can we file a version that is still under MFDS review?
Not on the reliance route. Reliance needs a valid reference approval at the time you file.
If you are planning Latin America from a Korean approval, our market access team can map the pathway and the local holder model country by country before you commit budget.
This article reflects regulations as published at the time of writing (November 2026). It is general information, not legal advice for a specific device.